Clonmel Healthcare reintroduces Famotidine Clonmel Otesanya David March 29, 2022

Clonmel Healthcare reintroduces Famotidine Clonmel

Clonmel Healthcare reintroduces Famotidine Clonmel

[ad_1]

Ranitidine products in Ireland were previously recalled in 2019

Following the recall of Ranitidine products in Ireland in 2019, Clonmel Healthcare is delighted to announce the re-introduction of Famotidine Clonmel 20mg and 40mg film-coated tablets, available on prescription to the Irish market.

Famotidine Clonmel is a H2-receptor antagonist indicated for the following:

  • Prevention of recurrent duodenal ulcers*
  • Duodenal ulcer
  • Benign gastric ulcer
  • Zollinger-Ellison-Syndrome
  • Symptomatic treatment of mild reflux oesophagitis*
  • Treatment of mild to moderate reflux oesophagitis**

Famotidine Clonmel is available on all reimbursement schemes including the GMS. The GMS codes are below:

  • Famotidine Clonmel 20mg Film-coated Tablets x 60: 44452
  • Famotidine Clonmel 40mg Film-coated Tablets x 30: 44453

Full prescribing information is available on request or alternatively please go to www.clonmel-health.ie.

Medicinal product subject to medical prescription.

Please contact Clonmel Healthcare on 01 620 4000 if you require any additional information.

*Refer to 20 mg SmPC. **Refer to 40 mg SmPC.

PA 126/344/001-2. PA Holder: Clonmel Healthcare Ltd., Clonmel, Co. Tipperary. Date prepared: March 2022. 2022/ADV/FAM/068H.

[ad_2]

Source link

Write a comment